Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

Feb 16, 2020
13 min read

Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare but potentially curable cause of pulmonary hypertension resulting from unresolved or recurrent pulmonary emboli. When clots fail to fully dissolve, they organize into fibrotic tissue that narrows or obstructs pulmonary arteries, increasing vascular resistance and pulmonary arterial pressure. Over time, this sustained hemodynamic stress leads to progressive right ventricular strain, reduced oxygenation, and, if untreated, right heart failure.

Definition and Mechanism

How does CTEPH develop?

Chronic thromboembolic pulmonary hypertension (CTEPH) arises when thromboembolic material becomes permanently embedded within the pulmonary arterial walls following an acute pulmonary embolism. Instead of normal fibrinolytic resolution, the clots transform into fibrotic, scar-like tissue that obstructs blood flow and remodels the vascular bed. This chronic obstruction triggers endothelial dysfunction, inflammation, and small-vessel arteriopathy that mirror the changes seen in idiopathic pulmonary arterial hypertension. The combined macrovascular and microvascular disease results in a sustained elevation of mean pulmonary artery pressure above 20 mmHg and increased pulmonary vascular resistance, impairing right ventricular function and systemic oxygen delivery.

Epidemiology and Predisposing Factors

Who is at risk for developing CTEPH?

Chronic thromboembolic pulmonary hypertension (CTEPH) can occur in anyone who has experienced a pulmonary embolism, though up to half of all patients diagnosed report no documented embolic event. Established risk factors include recurrent or unprovoked venous thromboembolism, splenectomy, inflammatory or infectious conditions such as osteomyelitis and inflammatory bowel disease, indwelling venous catheters or shunts, thyroid hormone replacement, malignancy, and thrombophilic disorders, including antiphospholipid antibody syndrome and elevated factor VIII levels. Persistent exertional dyspnea, hypoxemia, or exercise intolerance three months or more after a pulmonary embolism should raise suspicion for CTEPH.

Prevalence and Diagnostic Gap

How frequently does CTEPH occur?

Epidemiologic analyses from the International Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Registry and multicenter cohort studies published through 2024 estimate that 3–4% of patients who survive an acute pulmonary embolism develop CTEPH within two years. This translates to roughly 5,000–6,500 new cases annually in the United States. However, the true incidence is likely higher because the condition remains frequently misdiagnosed as asthma, deconditioning, or other cardiopulmonary disorders. Global prevalence is estimated at approximately 30 per million people, but underrecognition and inconsistent post-embolic follow-up conceal much of the disease burden.

Hemodynamic Consequences and Clinical Impact

What effects does CTEPH have on the body?

Persistent vascular obstruction in chronic thromboembolic pulmonary hypertension (CTEPH) increases resistance within the pulmonary arterial system, forcing the right ventricle to generate greater pressure to sustain pulmonary perfusion. This chronic pressure overload leads to right ventricular hypertrophy, dilation, tricuspid regurgitation, and eventual right-sided heart failure. As pulmonary blood flow slows, oxygen transfer across the alveolar membrane declines, resulting in exertional dyspnea, fatigue, and hypoxemia. Untreated CTEPH is a progressive and fatal condition, but when identified early, surgical pulmonary endarterectomy or balloon pulmonary angioplasty can normalize hemodynamics, improve oxygenation, and markedly extend survival.

Underlying Pathogenesis

What biological processes cause CTEPH?

Chronic thromboembolic pulmonary hypertension (CTEPH) develops from the failure of normal fibrinolysis following a pulmonary embolic event. Under typical conditions, endogenous fibrinolytic enzymes—principally plasmin activated from plasminogen—dissolve thrombotic material and restore vessel patency. In CTEPH, this resolution process is disrupted. The residual thrombus undergoes fibrotic transformation, integrating into the pulmonary arterial wall and producing fixed mechanical obstruction. This localized scarring narrows or occludes major and segmental arteries, while downstream regions experience compensatory microvascular remodeling, including endothelial dysfunction, medial hypertrophy, and in situ thrombosis. These cumulative vascular changes sustain elevated pulmonary vascular resistance, impair oxygen diffusion, and generate progressive right ventricular overload.

Contemporary molecular studies have linked CTEPH to intrinsic abnormalities in the fibrinolytic system—elevated factor VIII, reduced tissue plasminogen activator (tPA) activity, and increased plasminogen activator inhibitor-1 (PAI-1)—as well as proinflammatory cytokine activation, notably interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α). This cytokine-mediated inflammation promotes endothelial injury, oxidative stress, and vascular fibrosis, reinforcing the chronic, self-perpetuating nature of the disease.

From a functional medicine perspective, CTEPH reflects a systemic imbalance between coagulation, inflammation, and endothelial health. Factors such as chronic inflammatory load, micronutrient deficiencies (notably vitamins C, D, and K2), oxidative stress, mitochondrial dysfunction, and hormonal or thyroid dysregulation can amplify endothelial activation and impair nitric oxide bioavailability—both critical in maintaining vascular tone and fibrinolytic efficiency. Elevated homocysteine levels, impaired methylation pathways, gut-derived inflammation, and metabolic dysfunction further contribute to a prothrombotic internal environment.

Addressing these upstream drivers through targeted nutritional, metabolic, and anti-inflammatory interventions is increasingly viewed as essential in comprehensive management, complementing conventional anticoagulant and surgical therapies to optimize vascular repair and restore endothelial equilibrium.

Predisposing and Clinical Risk Factors

Who is more likely to develop CTPH?

While any patient with a history of pulmonary embolism can develop CTEPH, certain biological, metabolic, and systemic factors substantially increase susceptibility. These influences extend beyond conventional hematologic risk and include functional imbalances that affect endothelial repair, inflammation, and fibrinolysis. Together, they shape a vascular environment that favors chronic thrombus persistence and arterial remodeling.

Documented risk modifiers include:

Non-O blood group: Associated with increased plasma levels of von Willebrand factor and factor VIII, heightening baseline coagulation activity and impairing fibrinolytic clearance.
Chronic infection or inflammation: Conditions such as osteomyelitis and inflammatory bowel disease sustain low-grade cytokine release (IL-6, TNF-α) and endothelial injury, fostering a prothrombotic state.
Malignancy: Active or prior cancers, particularly adenocarcinomas, trigger systemic hypercoagulability through tumor-derived tissue factor and inflammatory mediators.
Female sex and hormonal influence: Estrogen exposure through pregnancy, hormonal contraception, or replacement therapy alters nitric oxide balance, platelet activity, and vascular tone, contributing to the observed female predominance in CTEPH registries.
Indwelling cardiac devices: Pacemaker leads, ventriculoatrial shunts, and infected prosthetic materials can generate chronic embolic or infectious foci.
Prothrombotic disorders: Antiphospholipid antibody syndrome, hyperhomocysteinemia, elevated factor VIII, and inherited thrombophilias (such as factor V Leiden) markedly increase clot persistence and vascular scarring.
Prior splenectomy: The absence of splenic filtration alters platelet morphology, elevates circulating microparticles, and increases thrombotic potential.
Thyroid dysfunction or replacement therapy: Both hypo- and hyperthyroid
states disrupt coagulation factor synthesis, platelet function, and endothelial stability.

From a functional medicine perspective, these risk factors exist within a broader framework of systemic dysregulation. Chronic inflammation, oxidative stress, mitochondrial inefficiency, and nutrient depletion—particularly deficiencies in vitamins C, D, and K2—compromise vascular resilience and fibrinolytic capacity. Elevated homocysteine and impaired methylation pathways reduce nitric oxide bioavailability and promote endothelial rigidity, while insulin resistance and gut-derived inflammation further perpetuate coagulative imbalance.

Recognizing these metabolic and inflammatory contributors reframes CTEPH not solely as a consequence of embolic history but as the product of a sustained physiologic environment favoring vascular injury and impaired repair. Integrating conventional management with targeted interventions to restore endothelial function, reduce inflammation, and correct metabolic deficiencies supports a more complete prevention and recovery strategy.

Clinical Manifestations

What symptoms indicate CTEPH?

Chronic thromboembolic pulmonary hypertension (CTEPH) develops gradually as unresolved thromboembolic obstruction and vascular remodeling elevate pulmonary pressures and strain the right ventricle. Symptoms emerge as both hemodynamic and systemic processes advance, reflecting not only mechanical vascular restriction but also inflammation, oxidative stress, endothelial dysfunction, and impaired cellular energy metabolism. This combination of structural and biochemical stressors produces a broad symptom profile that overlaps cardiopulmonary and metabolic systems.

Common clinical features include:

Progressive exertional dyspnea: The earliest and most consistent symptom, driven by elevated pulmonary pressures and reduced alveolar-capillary gas exchange. From a functional standpoint, impaired mitochondrial efficiency and low nitric oxide bioavailability further limit oxygen utilization in skeletal muscle, compounding breathlessness even at mild exertion.
Fatigue and reduced exercise tolerance: Caused by diminished cardiac output and tissue hypoxia. Systemic inflammation, micronutrient depletion (particularly B vitamins, magnesium, and coenzyme Q10), and mitochondrial dysfunction reduce cellular ATP generation, magnifying exhaustion and slowing recovery.
Chest discomfort or pressure: A result of right ventricular dilation and increased wall stress. Functional mechanisms, such as endothelial inflammation and autonomic imbalance, contribute to vascular rigidity and increased cardiac workload.
Palpitations: Triggered by right atrial enlargement and arrhythmia. Chronic stress, thyroid imbalance, and adrenal dysregulation can exacerbate palpitations through altered catecholamine signaling and electrolyte instability.
Presyncope or syncope: Indicative of advanced hemodynamic compromise and fixed cardiac output. Functional contributors include impaired baroreceptor sensitivity and dysautonomia secondary to chronic hypoxia and oxidative stress.
Peripheral edema and leg swelling: Caused by venous congestion from right-sided heart failure. Elevated aldosterone levels, sodium retention, and systemic inflammation worsen fluid accumulation, which can be mitigated by supporting lymphatic drainage and vascular tone.
Cyanosis or digital discoloration: Reflects severe desaturation and peripheral hypoperfusion. Endothelial dysfunction and reduced nitric oxide synthesis diminish microvascular dilation, worsening cyanotic changes.
Hemoptysis: Rare but potentially life-threatening, resulting from rupture of hypertrophied bronchial vessels under elevated pulmonary pressure. Chronic inflammation and vascular fragility increase susceptibility to this event.

The gradual onset and multifactorial nature of these symptoms frequently lead to misdiagnosis as asthma, anxiety, or deconditioning. Recognizing the interconnected cardiovascular, metabolic, and inflammatory mechanisms underlying CTEPH allows for more precise and integrative management—combining conventional hemodynamic interventions with therapies that restore endothelial integrity, improve mitochondrial function, and correct systemic inflammatory and nutrient imbalances.

Diagnosis and Testing

How is CTEPH diagnosed?

Accurate diagnosis of chronic thromboembolic pulmonary hypertension (CTEPH) requires a structured, stepwise evaluation combining hemodynamic assessment, advanced imaging, and functional testing. Because symptoms are often nonspecific and overlap with other cardiopulmonary disorders, early recognition depends on a high index of suspicion—particularly in any patient with persistent dyspnea three months or longer after a pulmonary embolism. The diagnostic approach distinguishes CTEPH from other forms of pulmonary hypertension (PH) by demonstrating both chronic thromboembolic obstruction and sustained pulmonary pressure elevation after adequate anticoagulation.

Initial Screening and Noninvasive Evaluation

Ventilation–perfusion (V/Q) scan: The V/Q scan remains the gold-standard screening tool for CTEPH and is recommended as the first-line test by the 2024 European Society of Cardiology (ESC) and European Respiratory Society (ERS) guidelines. A normal scan virtually excludes the diagnosis, while segmental or larger mismatched perfusion defects strongly suggest residual thromboembolic disease. Modern SPECT-V/Q imaging has improved sensitivity and spatial resolution, enabling detection of early perfusion abnormalities even when CT angiography appears normal.
Transthoracic echocardiogram (TTE): Echocardiography assesses right ventricular size, wall thickness, and systolic pressure estimates. Findings such as right ventricular dilation, interventricular septal flattening, and tricuspid regurgitation velocity above 2.8 m/s support the presence of pulmonary hypertension but are not diagnostic of CTEPH alone.
Pulmonary function tests (PFTs): PFTs are typically normal or show only mild restriction in CTEPH, helping differentiate the condition from parenchymal lung diseases. A reduced diffusing capacity for carbon monoxide (DLCO) may indicate microvascular remodeling.

Confirmatory and Hemodynamic Assessment

Right heart catheterization (RHC): RHC is required for definitive diagnosis, providing direct measurement of mean pulmonary artery pressure (>20 mmHg), pulmonary arterial wedge pressure (≤15 mmHg), and pulmonary vascular resistance (≥2 Wood units). It also assesses cardiac output, right atrial pressure, and vasodilator responsiveness. Combined with imaging, RHC establishes disease severity and surgical operability.
CT pulmonary angiography (CTPA): High-resolution CTPA delineates chronic thromboembolic lesions—such as webs, bands, pouch defects, and abrupt vessel tapering—and maps their distribution within the pulmonary arterial tree. Modern dual-energy CT allows concurrent perfusion mapping, enhancing diagnostic accuracy and preoperative planning.
Digital subtraction pulmonary angiography (DSPA): Considered the gold standard for anatomical confirmation, DSPA provides superior visualization of segmental and subsegmental arteries, essential for assessing surgical candidacy and guiding balloon pulmonary angioplasty (BPA).
Magnetic resonance imaging (MRI): MRI provides noninvasive quantification of right ventricular mass, function, and strain. Four-dimensional flow MRI and contrast-enhanced perfusion mapping are emerging tools for evaluating hemodynamic impact and microvascular remodeling without ionizing radiation.
Exercise or cardiopulmonary stress testing: Cardiopulmonary exercise testing (CPET) evaluates exercise limitation, oxygen kinetics, and ventilatory efficiency. Abnormal patterns—such as elevated dead space ventilation and reduced peak VO₂—help differentiate CTEPH from deconditioning and other causes of dyspnea.

Current Diagnostic Advancements and Functional Integration

Recent research emphasizes the importance of integrating structural imaging with metabolic and endothelial biomarkers to improve early detection. Studies published in the European Heart Journal (2024) highlight the role of elevated factor VIII, NT-proBNP, and growth differentiation factor-15 (GDF-15) in identifying subclinical right ventricular stress. Functional medicine approaches complement conventional testing by assessing underlying contributors that impair vascular repair and fibrinolysis, such as chronic inflammation, thyroid imbalance, elevated homocysteine, and oxidative stress markers (8-isoprostane, CRP, MPO).

A comprehensive diagnostic model now combines imaging, hemodynamic data, and metabolic profiling to identify both the structural burden of CTEPH and the systemic processes that perpetuate vascular dysfunction. Early multidisciplinary evaluation at an expert CTEPH center remains the strongest determinant of curative outcomes.

Management and Treatment

How is CTEPH treated?

Management of chronic thromboembolic pulmonary hypertension (CTEPH) requires a comprehensive, multidisciplinary strategy integrating surgical, interventional, pharmacologic, and functional medicine approaches. Treatment focuses on removing or reducing vascular obstruction, lowering pulmonary pressures, restoring right ventricular function, and correcting systemic factors—such as inflammation, oxidative stress, and endothelial dysfunction—that perpetuate the disease process and increase the risk of recurrence.

There are two primary interventional options:

Pulmonary endarterectomy (PEA): PEA remains the definitive and potentially curative procedure for CTEPH. It involves open surgical removal of organized fibrotic thromboembolic material from the pulmonary arteries under deep hypothermic circulatory arrest. When performed in expert centers, mortality rates are below 5%, and five-year survival exceeds 90%. A successful PEA can normalize pulmonary pressures and reverse right ventricular remodeling.

From a functional medicine perspective, pre- and postoperative optimization is essential. Targeted anti-inflammatory nutrition, mitochondrial support (CoQ10, ribose, magnesium, and carnitine), and antioxidant therapy (vitamin C, N-acetylcysteine, glutathione precursors) reduce endothelial injury and improve vascular repair. Stress modulation and circadian rhythm regulation help stabilize autonomic tone and oxygen utilization during recovery.
Balloon pulmonary angioplasty (BPA): For patients with distal or surgically inaccessible disease, BPA is a minimally invasive alternative that uses catheter-based balloon dilation to restore pulmonary blood flow. Performed in staged sessions, BPA can reduce pulmonary vascular resistance by up to 70% and significantly improve oxygenation and exercise capacity. The 2024 European Respiratory Journal consensus recommends BPA as first-line therapy in inoperable cases or as adjunct treatment after incomplete surgical clearance.

Functional adjuncts include mitochondrial energy support and microcirculatory enhancement with nutraceuticals such as L-arginine, beetroot extract (a natural nitrate source), and omega-3 fatty acids, which support nitric oxide synthesis and vascular elasticity.

Do I have additional CTEPH treatment options?

Pharmacologic therapy: For patients who are not surgical candidates or have persistent pulmonary hypertension after intervention, riociguat remains the cornerstone of medical therapy. As a soluble guanylate cyclase stimulator, it enhances the nitric oxide–cGMP pathway, improving vasodilation and lowering pulmonary vascular resistance. Clinical trials (CHEST-1 and CHEST-2) demonstrated improvements in functional capacity, WHO class, and hemodynamics. Other drugs—including prostacyclin analogues, endothelin receptor antagonists, and phosphodiesterase-5 inhibitors—may be added in advanced or refractory disease under specialist supervision.
Functional and integrative treatment protocols: CTEPH is both a vascular and metabolic disorder, and addressing systemic contributors can improve endothelial function, oxygen utilization, and recovery. Integrative interventions include:
- Anti-inflammatory nutrition: A Mediterranean or plant-forward diet rich in omega-3 fatty acids, flavonoids, and antioxidants reduces IL-6 and TNF-α–mediated vascular inflammation.
- Micronutrient and mitochondrial repletion: Supplementation with vitamins D, K2, C, and B-complex, along with CoQ10, magnesium, and alpha-lipoic acid, supports endothelial nitric oxide synthesis and ATP production.
- Hormonal and thyroid balance: Normalizing thyroid function, cortisol rhythm, and estrogen metabolism reduces coagulability and stabilizes vascular tone.
- Gut-liver axis optimization: Addressing dysbiosis and hepatic detoxification supports inflammatory resolution and estrogen clearance, reducing thrombotic signaling.
- Stress physiology and oxygen regulation: Mindfulness, paced breathing, and low-intensity aerobic conditioning improve autonomic regulation and pulmonary perfusion efficiency.
- Detoxification and oxidative repair: Use of glutathione, N-acetylcysteine, and curcumin assists in neutralizing reactive oxygen species that drive endothelial dysfunction.

This functional integration complements conventional care by targeting the upstream pathophysiology that fuels thrombosis, fibrosis, and vascular rigidity, helping prevent recurrence and improve overall hemodynamic stability.

Outlook and Prognosis

What is the outlook for patients who have CTEPH?

When diagnosed early and treated appropriately, chronic thromboembolic pulmonary hypertension (CTEPH) is one of the few forms of pulmonary hypertension that can be cured or fully stabilized. Following pulmonary endarterectomy or staged BPA, most patients achieve near-normal pulmonary hemodynamics, restored exercise tolerance, and markedly improved survival. Modern five-year survival exceeds 90% for operable patients and continues to rise with combined procedural and pharmacologic strategies.

For those ineligible for surgery, outcomes improve significantly with a comprehensive medical and functional protocol. Targeted pharmacotherapy, vascular rehabilitation, and systemic optimization—through anti-inflammatory nutrition, metabolic rebalancing, and stress modulation—enhance quality of life and reduce disease progression.

Persistent anxiety and depression are common, particularly among inoperable patients or those living with chronic symptoms. Addressing psychological recovery through integrative therapies, such as cognitive-behavioral therapy, mindfulness-based interventions, and community support, improves adherence, resilience, and long-term outcomes.

Ultimately, the prognosis of CTEPH depends not only on procedural success but on the restoration of systemic vascular health. Combining conventional medicine with functional strategies that repair endothelial integrity, balance metabolic pathways, and stabilize autonomic function represents the most complete and sustainable model of recovery available today.

Prevention

Is CTEPH preventable?

Chronic thromboembolic pulmonary hypertension (CTEPH) develops as a complication of unresolved or recurrent pulmonary emboli, but many contributing factors are modifiable. While not all cases can be prevented—especially those linked to inherited thrombophilias or structural cardiovascular disease—reducing systemic inflammation, maintaining vascular health, and supporting the body’s natural anticoagulant and fibrinolytic mechanisms can meaningfully lower risk.

Evidence from the European Heart Journal (2024) and CHEST (2023) shows that early recognition and comprehensive management of acute pulmonary embolism remain the most effective preventive measures. Prevention strategies integrate conventional medicine with functional optimization of vascular and metabolic health:

Consistent anticoagulation: Strict adherence to anticoagulant therapy following a pulmonary embolism is the strongest defense against chronic thrombus formation. Regular monitoring ensures therapeutic stability, whether using warfarin or direct oral anticoagulants.
Smoking cessation and toxin avoidance: Eliminating tobacco and minimizing exposure to environmental pollutants or heavy metals protects endothelial function and enhances oxygen transport.
Inflammation control: Managing autoimmune, thyroid, or gastrointestinal inflammatory conditions reduces cytokine-driven endothelial injury and prothrombotic signaling.
Nutritional and metabolic balance: Diets rich in antioxidants, omega-3 fatty acids, and polyphenols—such as the Mediterranean diet—improve fibrinolytic efficiency and vascular elasticity. Supplementing vitamins D, K2, C, and B-complex supports nitric oxide production and homocysteine regulation.
Hormonal and thyroid regulation: Balancing estrogen, cortisol, and thyroid hormones prevents the metabolic and vascular dysregulation that increases clot risk.
Gut and liver health: Optimizing microbiome integrity and hepatic detoxification reduces systemic inflammation and promotes balanced coagulation.
Regular movement: Walking, cycling, or gentle strength training improves venous return and lowers the likelihood of stasis-related thrombosis.

Functional prevention emphasizes vascular resilience—supporting the body’s own fibrinolytic capacity, restoring redox balance, and maintaining endothelial flexibility—so that acute clotting events do not evolve into chronic vascular obstruction.

Living With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

What are the most important things to know about living with CTEPH?

Living with chronic thromboembolic pulmonary hypertension (CTEPH) requires lifelong attention to both vascular and systemic health. Most patients remain on long-term anticoagulation to prevent recurrent thromboembolism and secondary vascular injury. For those prescribed warfarin, maintaining consistent vitamin K intake rather than avoidance is now preferred, as stability—not restriction—optimizes anticoagulant control. Direct oral anticoagulants may be considered when appropriate based on individual risk profiles.

Daily habits that support recovery and cardiovascular stability are central to long-term wellness. These include:

Therapeutic movement: Light aerobic activity, such as walking, yoga, or swimming, enhances oxygen efficiency, venous circulation, and emotional well-being. Pulmonary rehabilitation programs, guided by cardiopulmonary specialists, safely build endurance and strength.
Anti-inflammatory nutrition: Emphasize whole foods rich in antioxidants, magnesium, and phytonutrients to reduce endothelial stress. Omega-3s, olive oil, turmeric, and leafy greens promote nitric oxide activity and vascular flexibility.
Mitochondrial and nutrient support: Supplementation with CoQ10, L-carnitine, vitamin D, and B-complex vitamins assists in restoring energy metabolism and oxygen utilization.
Breath regulation and stress balance: Practices such as diaphragmatic breathing, meditation, and paced respiration improve pulmonary efficiency, autonomic regulation, and right ventricular function.
Sleep and circadian health: Adequate, high-quality sleep lowers inflammatory load and stabilizes blood pressure variability.
Emotional and psychological care: Anxiety and depression are common in chronic cardiopulmonary disease. Integrative therapies—including mindfulness, counseling, and peer support—help maintain resilience and adherence to treatment.

Living well with CTEPH requires a holistic model that combines conventional anticoagulation, pulmonary rehabilitation, and functional optimization of inflammation, metabolism, and vascular repair. This multidimensional approach not only prevents progression but also promotes long-term cardiopulmonary strength, cognitive clarity, and quality of life.

The IWBCA provides the information and materials on this site for educational and informational purposes only. The content is not a substitute for professional medical evaluation, diagnosis, or treatment. Always consult your physician or another qualified healthcare provider regarding any questions you may have about a medical condition, diagnosis, or course of treatment. Do not disregard, delay, or alter medical advice based on information obtained from this site. If you believe you are experiencing a medical emergency, call 911 or your local emergency services immediately.